Kristen Proverb
Critical Care Medicine · Lowell, MANPI 1992867873
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,236 of the $3,635 with a category attached, or 61.5%. 14 manufacturers reported payments, led by Pacira Pharmaceuticals Incorporated at 32.8% of the total. Reporting peaked in 2021 at $1,367 and has fallen 87.1% since, to $177 in 2025.
Across 54 payments — averaging $67.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$1K
- Heron Therapeutics, Inc.$438
- Johnson & Johnson$376
- Vericel Corporation$358
- Miach Orthopaedics, Inc.$308
- Xiros Inc$263
- plus $700 from 8 others
What the payments were for
- Consulting fees$70019%
- Speaking & faculty fees$1143%
- Travel & lodging$56616%
- Food & beverage$2,23662%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 11 | $1,193 |
| Heron Therapeutics, Inc. | 1 | $438 |
| Johnson & Johnson(2 entities) | 19 | $376 |
| Vericel Corporation | 3 | $358 |
| Miach Orthopaedics, Inc. | 2 | $308 |
| Xiros Inc | 1 | $263 |
| Linvatec Corporation | 3 | $221 |
| Bioventus LLC | 3 | $189 |
| Smith+Nephew | 2 | $95 |
| Moximed, Inc | 2 | $52 |
| Baudax Bio Inc. | 2 | $43 |
| Pacira Therapeutics, Inc. | 2 | $38 |
| Stryker | 1 | $32 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IOVERA SYSTEM$566
- Zynrelef$438
- MACI$358
- Iovera$280
- BioBrace 23mm$175
- Durolane$152
- Zilretta$110
How this compares
$3,635 in reported general payments places this provider in the 85th percentile of 158 critical care medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 18 | $545 |
| Tranexamic Acid | 21 | $532 |
| Oxycodone Hcl | 123 | $362 |
| Omeprazole | 19 | $177 |
| Gabapentin | 81 | $118 |
| Meloxicam | 68 | $74 |
| Tramadol Hcl | 15 | $30 |
| Amoxicillin | 17 | $21 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Lowell
- Richard ChannickBoston$638K
- Ioana PrestonBurlington$544K
- Mark TidswellSpringfield$135K
- Benjamin MedoffBoston$98K
- Jerome CrowleyBoston$38K
- William McGeeSpringfield$32K
- Diana Espinoza BarreraBoston$17K
- Raghu SeethalaWeymouth$14K
- Catherine FioreBoston$13K
- Ilana KrummBoston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.